Skip to main content
SpringerLink
Log in

Basic Pharmacology of Desmopressin

A Review

  • Section 1: Desmopressin in Disorders of Diuresis
  • Published:
Drug Investigation Aims and scope Submit manuscript

Summary

Desmopressin is an analogue of the antidiuretic hormone vasopressin. The structural changes introduced in the molecule have eliminated the pressor activity of vasopressin and potentiated the antidiuretic action. The metabolic stability of the peptide is also increased. Thus, the plasma half-life for desmopressin is 55 minutes compared with a few minutes for vasopressin. The potent antidiuretic activity of desmopressin makes the peptide ideal for the treatment of cranial diabetes insipidus. However, it may also be used for nocturnal enuresis and as a diagnostic agent in determining renal concentrating capacity. Desmopressin has recently been shown to be successful in the treatment of certain bleeding disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Åberg M, Nilsson IM, Vilhardt H. The release of fibrinolytic activator and factor VIII after injection of DDAVP. In Davidson JF (Ed.) Progress in chemical fibrinolysis and thrombolysis, pp. 92–97, Churchill Livingstone, London and New York, 1979

    Google Scholar 

  • Aronson AS, Andersson KE, Bergstrand CG, Mulder JL. Treatment of diabetes insipidus in children with DDAVP, a synthetic analogue of vasopressin. Acta Paediatrica Scandinavica 62: 133–140, 1973

    Article  PubMed  CAS  Google Scholar 

  • Aronson AS, Svenningsen NW. DDAVP test for estimation of renal concentrating capacity in infants and children. Archives of Disease in Childhood 49: 654–659, 1974

    Article  PubMed  CAS  Google Scholar 

  • Aunsholt NA, Vilhardt H, Schmidt EB. Plasma half-life of DDAVP in uraemic patients. Acta Pharmacologica et Toxicologica 59: 332–333, 1986

    Article  PubMed  CAS  Google Scholar 

  • Becker DJ, Foley TP. The effect of water deprivation and water loading during treatment with 1-deamino-8-D-arginine vasopressin in central diabetes insipidus in childhood. Acta Endocrinologica 97: 358–360, 1981

    PubMed  CAS  Google Scholar 

  • Belmaker RH, Bleich A. The use of desmopressin in adult enuresis. Military Medicine 151: 660–662, 1986

    PubMed  CAS  Google Scholar 

  • Burrow GN, Wassenaar W, Robertson GL, Sehl H. Treatment of diabetes insipidus during pregnancy. Acta Endocrinologica 97: 23–25, 1981

    PubMed  CAS  Google Scholar 

  • Carvounis CP, Franki N, Levine SD, Hays RM. Membrane pathways for water and solutes in the toad bladder. Journal of Membrane Biology 49: 253–268, 1979

    Article  PubMed  CAS  Google Scholar 

  • Chirman SB, Kinsell LW. Diabetes insipidus. Treatment with 8-lysine vasopressin in a nasal spray. California Medicine 101: 1–3, 1964

    PubMed  CAS  Google Scholar 

  • Curtis JR, Donovan BA. Assessment of renal concentrating ability. British Medical Journal 1: 304–305, 1979

    Article  PubMed  CAS  Google Scholar 

  • du Vigneaud V, Gish DT, Katsoyannis PG. A synthetic preparation possessing biological properties associated with arginine vasopressin. Journal of the American Chemical Society 76: 4751–4752, 1954

    Article  Google Scholar 

  • Editorial. Desmopressin and arterial thrombosis. Lancet 1: 938–939, 1989

  • Edwards CRW, Kitau MJ, Chard T, Besser GM. Vasopressin analogue DDAVP in diabetes insipidus: clinical and laboratory studies. British Medical Journal 3: 375–378, 1973

    Article  PubMed  CAS  Google Scholar 

  • Fjellestad-Paulsen A, Wille S, Harris AS. Comparison of intranasal and oral desmopressin for nocturnal enuresis. Archives of Disease in Childhood 62: 674–677, 1987

    Article  PubMed  CAS  Google Scholar 

  • Frank JP. De curandis hominum morbis, III, classis V (profluvia), ordo I (profluvia serosa), genus II (diabetes). Caen et Socios, lorence, 1794

    Google Scholar 

  • Hammer M, Vilhardt H. Peroral treatment of diabetes insipidus with a polypeptide analog, desmopressin. Journal of Pharmacology and Experimental Therapeutics 234: 754–760, 1985

    PubMed  CAS  Google Scholar 

  • Harris AS, Hedner P, Vilhardt H. Nasal administration of desmopressin by spray and drops. Journal of Pharmaceutical Pharmacology 39: 932–934, 1987

    Article  CAS  Google Scholar 

  • Hays RM, Sasaki J, Tilles SM, Meiteles L, Franki N. Morphological aspects of the cellular action antidiuretic hormone. In Schrier RW (Ed.) Vasopressin, pp. 79–87, Raven Press, New York, 1985

    Google Scholar 

  • Jard S, Bockaert J, Butlen D, Rajerison R, Roy C. Vasopressin-sensitive adenylate cyclase from the mammalian kidney. In Klinge E (Ed.), Proceedings of the 6th International Congress of Pharmacology, Vol. I, Receptors and cellular pharmacology, pp. 121–130, Pergamon Press, New York, 1976

    Google Scholar 

  • Kachadorian WA. Prostaglandin synthesis, intramembranous particle aggregates and water permeability in toad urinary bladder. Kidney International 23: 258, 1983

    Google Scholar 

  • Kamm O, Aldrich TB, Grote IW, Rowe LW, Bugbee EP. The active principle of the posterior lobe of the pituitary gland, I the demonstration of the presence of two active principles, II the separation of the two principles and their concentration in the form of potent solid preparations. Journal of the American Chemical Society 50: 573–601, 1928

    Article  CAS  Google Scholar 

  • Liard J-F. Effects of a specific antidiuretic agonist on cardiac output and its distribution in intact and anephric dogs. Clinical Science 74: 293–299, 1988

    PubMed  CAS  Google Scholar 

  • Mannucci PM, Åberg M, Nilsson IM, Robertson B. Mechanism of plasminogen activator and factor VIII increase after vaso-active drugs. British Journal of Haematology 30: 81–93, 1975

    Article  PubMed  CAS  Google Scholar 

  • Mannucci PM, Lusher JM. Desmopressin and thrombosis. Lancet 2: 675–676, 1989

    Article  PubMed  CAS  Google Scholar 

  • Mannucci PM, Remuzzi G, Pusineri F, Lombardi R, Valsecchi C, et al. Deamino-8-D-arginine vasopressin shortens the bleeding time in uraemia. New England Journal of Medicine 308: 8–12, 1983

    Article  PubMed  CAS  Google Scholar 

  • Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. DDAVP in haemophilia. Lancet 2: 1171–1172, 1977

    Article  PubMed  CAS  Google Scholar 

  • Moses AM. Synthetic vasopressin nasal spray in the treatment of diabetes insipidus. Clinical Pharmacology and Therapeutics 5: 422–427, 1964

    PubMed  CAS  Google Scholar 

  • Nilsson IM, Vilhardt H, Holmberg L, Åstedt B. Association between factor VIII related antigen and plasminogen activator. Acta Medica Scandinavica 211: 105–112, 1982

    Article  PubMed  CAS  Google Scholar 

  • Nilsson IM, Walter H, Mikaelsson M, Vilhardt H. Factor VIII concentrate prepared from DDAVP stimulated blood donor plasma. Scandinavian Journal of Haematology 22: 42–46, 1979

    Article  PubMed  CAS  Google Scholar 

  • Oravec D, Lichardus B. Management of diabetes insipidus in pregnancy. British Medical Journal 4: 114–115, 1972

    Article  PubMed  CAS  Google Scholar 

  • Pedersen PS, Hejl M, Kjøller SS. Desamino D arginine vasopressin in childhood nocturnal enuresis. Journal of Urology 133: 65–66, 1985

    PubMed  CAS  Google Scholar 

  • Pliska V, Vilhardt H. Design of DDAVP: the pathway between ideas and pharmacologic reality. In Sutor AH (Ed.) DDAVP in bleeding disorders, pp. 12–29, Schattauer Verlag, Stuttgart and New York, 1980

    Google Scholar 

  • Rittig S, Knudsen UB, Jenler M, Nørgaard JP, Pedersen EB, et al. Adult enuresis. The role of vasopressin and atrial natriuretic peptide. Scandinavian Journal of Urology and Nephrology, Supplement 125: 79–86, 1989b

    PubMed  CAS  Google Scholar 

  • Rittig S, Knudsen UB, Nørgaard JP, Pedersen EB, Djurhus JC. Abnormal diurnal rhythm of plasma vasopressin and urinary output in patients with enuresis. American Journal of Physiology 256: 664–671, 1989a

    Google Scholar 

  • Robinson AG. DDAVP in the treatment of central diabetes insipidus. New England Journal of Medicine 294: 507–511, 1976

    Article  PubMed  CAS  Google Scholar 

  • Salzman EW, Weinstein MJ, Weintraub RM, Ware JA, Thurer RL, et al. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. New England Journal of Medicine 324: 1402–1406, 1986

    Article  Google Scholar 

  • Schlondorff D, Franki N. Effect of vasopressin on cyclic AMP-dependent protein kinase in toad urinary bladder. Biochimica Biophysica Acta 628: 1–12, 1980

    Article  CAS  Google Scholar 

  • Seif SM, Zeuser TV, Ciarochi FF, Davis BB, Robinson AF. DDAVP (1-desamino-8-D-arginine-vasopressin) treatment of central diabetes insipidus — mechanism of prolonged action. Journal of Clinical Endocrinology and Metabolism 46: 381–388, 1978

    Article  PubMed  CAS  Google Scholar 

  • Vilhardt H, Bie P. Antidiuretic effect of perorally administered DDAVP in hydrated humans. Acta Endocrinologica 105: 474–476, 1984

    PubMed  CAS  Google Scholar 

  • Vilhardt H, Lundin S, Falch J. Plasma kinetics of DDAVP in man. Acta Pharmacologica et Toxicologica 58: 379–381, 1986

    Article  PubMed  CAS  Google Scholar 

  • von den Velden R. Die Nierenwirkung von Hypophysenextrakten beim Menschen. Berliner Klinische Wochenschrift 2: 2083–2086, 1913

    Google Scholar 

  • Wade JB. Hormonal modulation of epithelial structure. In Ussing HH, et al. (Eds) Water transport across epithelia, pp. 422–436, Munksgaard, Copenhagen, 1981

    Google Scholar 

  • Warrior AI, Lusher JM. DDAVP: a useful alternative to blood components in moderate hemophilia A and von Willebrand’s disease. Journal of Pediatrics 102: 228–233, 1983

    Article  Google Scholar 

  • Zaoral M, Kolc J, Sorm F. Amino acids and peptides LXXI. Synthesis of 1-deamino-8-D-amino-butyrine vasopressin, 1-deamino-8-D-lysine vasopressin and 1-deamino-8-D-arginine vasopressin. Collection of Czechoslovak Chemical Communications 32: 1250–1257, 1967

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Physiology, Panum Institute, University of Copenhagen, Blegdamsvej 3C, 2200, Copenhagen N, Denmark

    Hans Vilhardt

Authors
  1. Hans Vilhardt
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vilhardt, H. Basic Pharmacology of Desmopressin. Drug Invest 2 (Suppl 5), 2–8 (1990). https://doi.org/10.1007/BF03258235

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03258235

Keywords

Search

Navigation